痹痛丸联合甲氨蝶呤治疗活动性类风湿关节炎的随机对照试验方案
本研究为多中心、随机、双盲、安慰剂对照临床试验,计划纳入120例活动性类风湿关节炎患者,比较痹痛丸与安慰剂联合甲氨蝶呤治疗3个月的疗效。主要结局包括ACR50率、DAS28变化及12个月改良Sharp评分变化,旨在为痹痛丸治疗活动性类风湿关节炎提供可靠证据。
要点
- 痹痛丸联合甲氨蝶呤治疗活动性类风湿关节炎的多中心随机双盲安慰剂对照试验。
- 计划纳入120例患者,治疗3个月,随访至12个月。
- 主要结局为ACR50率、DAS28变化和改良Sharp评分变化。
核心结论
- 该试验旨在为痹痛丸治疗活动性类风湿关节炎的疗效提供可靠证据。
- 目前痹痛丸虽在中国广泛用于活动性类风湿关节炎,但缺乏共识性疗效证据。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验。
- 计划纳入120例活动性类风湿关节炎患者,治疗3个月。
- 试验注册于ClinicalTrials.gov,注册号NCT02885597,注册日期2016年8月30日。
关键数值与推荐
- 主要结局指标:ACR50率、从基线至3个月的DAS28变化、从基线至12个月的van der Heijde改良Sharp评分变化。
- 次要结局指标:ACR20和ACR70变化率、HAQ-DI、患者关节炎疼痛评估、患者整体关节炎评估及雅典失眠量表评分从基线至2周、1个月、2个月、3个月、6个月和12个月随访的变化。
- 次要结局还包括ACR50和DAS28从基线至2周、1个月、2个月、6个月和12个月随访的变化率(评分)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by swelling and painful joints, eventually leading to joint destruction. There is still a lack of effective therapy to treat RA. The Juanbi pill is a Chinese medicine that has been widely used to treat active RA in China for hundreds of years, relieving pain and protecting the affected joints from malformation. However, there is no solid evidence to show the effect of the Juanbi pill on the management of active RA. METHODS/DESIGN: We will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to determine whether the traditional Chinese medicine Juanbi pill could relieve joint pain in RA and protect the joints. A total of 120 patients with active RA will be enrolled and treated with the Juanbi pill or a placebo for 3 months. The primary outcome measures are as follows: rate of in the American College of Rheumatology (ACR)50, change in the 28-joint Disease Activity Score (DAS28) from baseline at beginning of therapy to 3 months, and a change in the van der Heijde modified Sharp score measured from baseline to 12 months. The secondary outcome measures are as follows: rate of change in ACR20, ACR70, Health Assessment Questionnaire-Disability Index (HAQ-DI), and change in score in the Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and the Athens Insomnia Scale (AIS) from baseline to 2-week, 1-month, 2-month, 3-month, 6-month, and 12-month follow up. In addition, the rate of change (score) in the ACR50 and DAS28 from the baseline to 2-week, 1-month, 2-month, 6-month, and 12-month follow up are also the secondary outcome measures. DISCUSSION: Although the Juanbi pill has been used in China for many years to treat RA, there is a lack of consensus about its effectiveness. This trial will provide convincing evidence about the effect of Juanbi pill on active RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02885597 . Registered on 30 August 2016.
引用
- Wang Q, Wang YR, Jia QY, et al. The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29558967. doi:10.1186/s13063-018-2555-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。